We will discuss novel pharmacological approaches targeting key pathways involved in NASH progression, including farnesoid X receptor (FXR) agonists, peroxisome proliferator-activated receptor (PPAR) agonists, and agents addressing metabolic dysfunction, inflammation, and fibrosis. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.